Patricia C. Hirano - Jul 17, 2024 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role
Officer title: Senior Vice President, Regulatory Affairs
Signature
/s/ Anish Bhatnagar, Attorney-in-Fact
Stock symbol
SLNO
Transactions as of
Jul 17, 2024
Transactions value $
$0
Form type
4
Date filed
7/19/2024, 09:02 AM
Previous filing
Jul 3, 2024
Next filing
Aug 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLNO Common Stock Award $0 +85K +174.34% $0.00 134K Jul 17, 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. 25% of the RSUs subject to the award shall vest on August 1, 2024, 25% of the RSUs subject to the award shall vest on the date that the U.S. Food and Drug Administration (FDA) accepts the Company's New Drug Application (NDA) for DCCR, and 50% of the RSUs subject to the award shall vest on the date that the FDA approves the Company's NDA for DCCR (the NDA Approval Date), subject to the Reporting Person continuing as a service provider through each such date.
F2 Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Remarks:

Officer title: Senior Vice President, Regulatory Affairs